Tuticorin Alkali (506808)

FairStock Score: 62/100 — STEADY

Score breakdown: P/E: 2/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• High return on capital: ROE 25.95% and ROCE 37.99% indicate strong capital efficiency.
• Strong growth momentum: sales up 19.94% and profit up 87.12%, with a PEG of 0.35.
• Piotroski F-Score of 7/9 suggests solid financial health across profitability, leverage, and efficiency metrics.
• Stock trading at its 52-week high shows current market confidence in the business.

Concerns

• Commodity chemical business likely has limited pricing power; margins can be cyclical and may reverse.
• Valuation is rich: P/B of 7.24 versus book value of ₹11.70 offers little margin of safety.
• Zero dividend yield means shareholders must rely entirely on future price appreciation.
• Promoter holding and debt/equity data are not available, making governance and balance-sheet risk hard to assess.

AI Analysis

Let me look at Tuticorin Alkali as an ownership stake. It is a commodity chemical producer, and that immediately lowers my excitement. Competitive advantages in commodity chemicals are rare; everyone sells a similar product, and pricing is set by supply and demand. The numbers are striking: ROE 25.95%, ROCE 37.99%, sales growth 19.94%, profit growth 87.12%, and a Piotroski F-score of 7/9. This is a financially healthy business, at least on recent evidence, and a PEG of 0.35 suggests the market is not paying full price for current growth. But I must be careful. P/B of 7.24 against book value of ₹11.70 means you are paying ₹84.67 for assets worth ₹11.70. Graham would demand a margin of safety, and this stock has none on a price-to-book basis. The P/E of 18.81 is not outrageous, but it is built on a sharp earnings upcycle. Profit grew 87% while sales grew only 20%; that implies margin expansion which, in a commodity cycle, often reverses. There is no dividend to cushion a patient shareholder. I also note promoter holding and debt/equity are not available; in a cyclical, capital-heavy chemical business, undisclosed debt is a red flag I cannot ignore. The latest quarter's ₹98 Cr sales and ₹9 Cr profit need to be seen over a full cycle. Is this a wonderful business? Possibly, but it is a cyclical one. If chemical prices soften, earnings and book value can shrink quickly. A good business and a good investment are different. At 7.24 times book, with no dividend and commodity risk, I would wait for a better price. This is a well-run cyclical at a full valuation.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer